Am J Psychiatry 1986; 143:1227-1233
Copyright © 1986 by American Psychiatric Association
Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital
HG Pope Jr, PE Keck Jr and SL McElroy
Neuroleptic malignant syndrome, a dangerous but little-known complication
of antipsychotic drugs, is often assumed to be rare. To assess the
frequency of the syndrome in a large psychiatric hospital, the authors
first reviewed the literature and developed operational diagnostic
criteria. Using these criteria to survey nearly 500 neuroleptic-treated
patients admitted during a 1-year period, they found that seven (1.4%) had
experienced definite or probable neuroleptic malignant syndrome. In several
cases, including one fatal case, the diagnosis of neuroleptic malignant
syndrome was not immediately considered. The authors conclude that
neuroleptic malignant syndrome may be more common than previously thought
and may be underdiagnosed.
This article has been cited by other articles:
|
|
|
|
 
J. R. Strawn, P. E. Keck Jr., and S. N. Caroff
Neuroleptic Malignant Syndrome
Am J Psychiatry,
June 1, 2007;
164(6):
870 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Chue
The relationship between patient satisfaction and treatment outcomes in schizophrenia.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
38 - 56.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. Ryan, S. W. Kidder, L. A. Daiello, and P. N. Tariot
Mental Health Services in Nursing Homes: Psychopharmacologic Interventions in Nursing Homes: What Do We Know and Where Should We Go?
Psychiatr Serv,
November 1, 2002;
53(11):
1407 - 1413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Suzuki, T. Kondo, K. Otani, K. Mihara, N. Yasui-Furukori, A. Sano, K. Koshiro, and S. Kaneko
Association of the TaqI A Polymorphism of the Dopamine D2 Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome
Am J Psychiatry,
October 1, 2001;
158(10):
1714 - 1716.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Ueda, M Hamamoto, H Nagayama, S Okubo, S Amemiya, and Y Katayama
Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome
J. Neurol. Neurosurg. Psychiatry,
July 1, 2001;
71(1):
111 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Ty and A. D. Rothner
Topical Review : Neuroleptic Malignant Syndrome in Children and Adolescents
J Child Neurol,
March 1, 2001;
16(3):
157 - 163.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. Kleinman and D. Schachter
Obtaining Informed Consent of Patients at Risk of Neuroleptic Malignant Syndrome
Psychiatr Serv,
September 1, 2000;
51(9):
1182 - 1183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Adnet, P. Lestavel, and R. Krivosic-Horber
Neuroleptic malignant syndrome
Br. J. Anaesth.,
July 1, 2000;
85(1):
129 - 135.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ueda, M. Hamamoto, H. Nagayama, K. Otsubo, C. Nito, T. Miyazaki, A. Terashi, and Y. Katayama
Susceptibility to neuroleptic malignant syndrome in Parkinson's disease
Neurology,
March 1, 1999;
52(4):
777 - 777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Pelonero, J. L. Levenson, and A. K. Pandurangi
Neuroleptic Malignant Syndrome: A Review
Psychiatr Serv,
September 1, 1998;
49(9):
1163 - 1172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kawanishi, T. Hanihara, Y. Shimoda, K. Suzuki, N. Sugiyama, H. Onishi, T. Miyakawa, Y. Yamada, and K. Kosaka
Lack of Association Between Neuroleptic Malignant Syndrome and Polymorphisms in the 5-HT1A and 5-HT2A Receptor Genes
Am J Psychiatry,
September 1, 1998;
155(9):
1275 - 1277.
[Abstract]
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1986
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
